Published on GHDx (https://ghdx.healthdata.org.)

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study

General Info

Geography 
Switzerland (CHE)
Geneva
Time period covered 
January, 2020 - December, 2020
Data type
Scientific literature
Keywords 
COVID-19, Disease outbreaks

Citation

Authors 
Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, De Ridder D, Petrovic D, Schrempft S, Marcus K, Yerly S, Arm Vernez I, Keiser O, Hurst S, Posfay-Barbe KM, Trono D, Pittet D, Gétaz L, Chappuis F, Eckerle I, Vuilleumier N, Meyer B, Flahault A, Kaiser L, Guessous I
Journal 
Lancet
Pages 
313-319
Publication year 
2020
Suggested citation 
Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, De Ridder D, Petrovic D, Schrempft S, Marcus K, Yerly S, Arm Vernez I, Keiser O, Hurst S, Posfay-Barbe KM, Trono D, Pittet D, Gétaz L, Chappuis F, Eckerle I, Vuilleumier N, Meyer B, Flahault A, Kaiser L, Guessous I. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020; 396(10247): 313-319.
Source URL:https://ghdx.healthdata.org./record/seroprevalence-anti-sars-cov-2-igg-antibodies-geneva-switzerland-serocov-pop-population-based#comment-0